Related Experiment Videos
Advances in oral therapy for type 2 diabetes
1Division of Diabetes and Endocrinology, Vanderbilt University Hospital, Nashville, TN 37232-6303, USA.
Postgraduate Medicine
|August 12, 2009
Summary
Tight glycemic control is crucial for diabetes mellitus patients, but can lead to hypoglycemia. Nateglinide shows promise in managing mealtime hyperglycemia by improving insulin release and reducing glucose spikes.
Area of Science:
- Endocrinology
- Pharmacology
- Metabolic Diseases
Background:
- Diabetes mellitus complications stem from poor glycemic control, impacting individuals and society.
- Current treatments like sulfonylureas and metformin have limitations including adverse effects and inability to manage comorbidities.
- Mealtime hyperglycemia management is a growing therapeutic focus.
Purpose of the Study:
- To evaluate nateglinide, an investigational agent, for managing mealtime hyperglycemia in diabetes mellitus.
- To assess nateglinide's efficacy in improving glycemic control and reducing glucose excursions.
Main Methods:
- Review of early data on nateglinide's pharmacokinetic and pharmacodynamic profile.
- Analysis of nateglinide's effect on insulin release and glucose levels during mealtime.
Main Results:
- Nateglinide demonstrates a rapid onset and short duration of action.
- It stimulates early mealtime insulin release effectively.
- Nateglinide significantly reduces post-meal glucose excursions, enhancing overall glycemic control.
Conclusions:
- Nateglinide is a promising agent for targeting mealtime hyperglycemia in diabetes management.
- Its mechanism offers a potential strategy to improve glycemic balance while mitigating risks associated with other agents.
- Further research is warranted to fully establish its role in comprehensive diabetes therapy.
Related Concept Videos
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:17Oral Hypoglycemic Agents: Sulfonylureas
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:22Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
01:24Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.